Spoken Alpha
Xencor Inc
Xencor designs engineered antibody therapeutics to treat cancer and autoimmune diseases. The company uses protein engineering to create XmAb drug candidates with improved properties and multi-target mechanisms, advancing them through clinical trials while partnering with pharmaceutical companies to develop and commercialize certain programs.
Xencor Inc is a Healthcare company operating in Biotechnology with a $1.82B market cap.
Most recent reported earnings: Q3 FY2026 (Nov 3, 2026).
12 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for XNCR.
$ curl https://api.spokenalpha.com/v1/companies/XNCRFAQ
Spoken Alpha indexes XNCR's earnings call transcripts at https://spokenalpha.com/companies/XNCR. Each call links to attributed speakers and parsed analyst Q&A. Xencor Inc's own investor relations page is at https://investors.xencor.com/.
Xencor Inc (XNCR) held its most recent earnings call on 2024-02-28, covering fiscal Q4 2023.
Xencor Inc (XNCR) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-03 | — | $-0.35 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-08-04 | $-0.29 | $-0.82 | +64.6% | $51.2M | — | — | EODHD |
| Q1 FY2026 | 2026-05-05 | $-1.71 | $-0.75 | -100.0% | $4.5M | — | — | EODHD |
| Q4 FY2025 | 2026-03-03 | $-0.09 | $-0.60 | +85.1% | $28.2M | — | — | EODHD |
| Q3 FY2025 | 2025-11-04 | $-0.08 | $-0.72 | +88.9% | $21.0M | — | — | EODHD |
| Q2 FY2025 | 2025-08-05 | $-0.41 | $-0.71 | +42.3% | $43.6M | — | — | EODHD |
| Q1 FY2025 | 2025-05-06 | $-0.66 | $-0.58 | -13.8% | $32.7M | — | — | EODHD |
| Q4 FY2024 | 2025-02-24 | $-0.62 | $-0.79 | +21.1% | $70.0M | — | — | EODHD |
| Q3 FY2024 | 2024-11-05 | $-0.71 | $-1.02 | +30.4% | $17.8M | — | — | EODHD |
| Q2 FY2024 | 2024-08-04 | $-1.07 | $-0.79 | -35.4% | $17.0M | — | — | EODHD |
| Q1 FY2024 | 2024-05-08 | $-1.11 | $-0.77 | -44.2% | $16.0M | — | — | EODHD |
| Q4 FY2023 | 2024-02-26 | $-0.31 | $-0.09 | -100.0% | $51.0M | — | — | EODHD |
| Q3 FY2023 | 2023-11-06 | $-0.40 | $-0.71 | +43.7% | $59.2M | — | — | EODHD |
| Q2 FY2023 | 2023-08-02 | $-0.37 | $-0.81 | +54.3% | $45.5M | — | — | EODHD |
| Q1 FY2023 | 2023-05-07 | $-1.02 | $-0.66 | -54.5% | $19.0M | — | — | EODHD |
| Q4 FY2022 | 2023-02-22 | $-0.20 | $-0.81 | +75.3% | $21.6M | — | — | EODHD |
| Q3 FY2022 | 2022-11-06 | $-0.55 | $-0.72 | +23.6% | $27.3M | — | — | EODHD |
| Q2 FY2022 | 2022-08-02 | $-0.57 | $-0.47 | -21.3% | $30.2M | — | — | EODHD |
| Q1 FY2022 | 2022-05-04 | $0.39 | $-0.45 | +100.0% | $85.5M | — | — | EODHD |
| Q4 FY2021 | 2022-02-22 | $1.21 | $-0.10 | +100.0% | $154.0M | — | — | EODHD |
Source: EODHD. XNCR reported actuals as published; sparse fields render as —.